science & platforms
Unlocking access to formerly undruggable cancer drivers
Frontier is developing precision medicines against important disease-causing proteins that the biopharma industry has not been able to drug with standard pharmaceutical interventions. We have established The FrontierTM Platform that leverages groundbreaking scientific approaches in chemoproteomics, covalent drug discovery, and machine learning to uncover and pharmacologically target pockets within disordered regions and cryptic binding sites on these proteins, making them accessible to therapeutic intervention by small-molecule drugs.
Tackling important disease drivers
Frontier’s initial focus is on the development of cancer therapeutics. Decades of research have identified critical cancer-causing proteins that to-date have not been successfully drugged. The need for truly novel classes of anti-cancer therapies remains high. There were an estimated 19.3 million new cancer cases and almost 10 million cancer deaths worldwide in 2020 (doi: 10.3322/caac.21660). Frontier’s precision medicines pipeline tackles the most important disease drivers and provide patients with novel, more effective precision cancer therapeutics.